2024-01-23 13:22:24 ET
Summary
- Replimune Group is developing virus-based treatments for solid tumors, particularly skin cancer.
- The company's RP1 treatment did not show significant improvement in response rates compared to standard care in a phase 1/2 study, though there is a signal of something buried therein.
- Replimune plans to initiate a confirmatory study for RP1 in melanoma patients and is also developing RP2 for uveal melanoma.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer